Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CTRV ContraVir Pharmaceuticals (CTRV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About ContraVir Pharmaceuticals Stock (NASDAQ:CTRV) 30 days 90 days 365 days Advanced Chart Ad TradingTipsTop 10 AI Stocks to Buy NowAre you ready to capitalize on the booming AI market? Our experts have identified the top 10 AI stocks set to skyrocket.Download our free report today Get CTRV alerts:Sign Up Key Stats Today's Range$0.60▼$0.6850-Day Range$2.53▼$3.5852-Week Range$3.52▼$91.00Volume18,905 shsAverage Volume432,822 shsMarket Capitalization$520,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.Read More… Top 10 AI Stocks to Buy Now (Ad)Are you ready to capitalize on the booming AI market? Our experts have identified the top 10 AI stocks set to skyrocket.Download our free report today Receive CTRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraVir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CTRV Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com CTRV Stock Analysis - Frequently Asked Questions How were ContraVir Pharmaceuticals' earnings last quarter? ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) issued its quarterly earnings results on Friday, May, 13th. The biopharmaceutical company reported ($1.12) EPS for the quarter, topping analysts' consensus estimates of ($1.80) by $0.68. When did ContraVir Pharmaceuticals' stock split? Shares of ContraVir Pharmaceuticals reverse split before market open on Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 28th 2018. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of ContraVir Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ContraVir Pharmaceuticals investors own include Ayala Pharmaceuticals (ADXS), Alliqua Biomedical (ALQA), Synergy Pharmaceuticals (SGYP), LadRx (CYTR), Madrigal Pharmaceuticals (MDGL), Palatin Technologies (PTN) and Protalix BioTherapeutics (PLX). Company Calendar Last Earnings5/13/2016Today11/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CTRV CUSIPN/A CIK1583771 Webwww.contravir.com Phone732-902-4000FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,450,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-4,810.77% Return on Assets-130.14% Debt Debt-to-Equity RatioN/A Current Ratio0.55 Quick Ratio0.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book0.81Miscellaneous Outstanding Shares800,000Free FloatN/AMarket Cap$520,000.00 OptionableNot Optionable Beta1.16 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:CTRV) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraVir Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraVir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.